31P-MRS and Huntington Disease (PRO-MH)
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
|Official Title:||31Phosphorus-Magnetic Resonance Spectroscopy and Huntington Disease|
- Brain energy deficit in Huntington patients [ Time Frame: one year ] [ Designated as safety issue: No ]
31P-MRS allows quantification of high-energy phosphate metabolites such as ATP and phosphocreatine.
Objective: to look at brain energy metabolism during rest and activation.
- Correlating a brain energy deficit with (i) biochemical parameters and (ii) clinical parameters in Huntington patients [ Time Frame: one year ] [ Designated as safety issue: No ]
Biochemical parameters include metabolites that we previously showed to be biomarkers in HD: branched chain amino acids and IGF1.
Clinical parameters include UHDRS and TFC.
|Study Start Date:||April 2011|
|Study Completion Date:||April 2012|
|Primary Completion Date:||April 2012 (Final data collection date for primary outcome measure)|
Other: 31P-MR spectroscopy
Brain energy deficit is quantified using 31P-MR spectroscopy
Other: 31P-RMN spectroscopy
Brain energy deficit is quantified using 31P-RMN spectroscopy
Please refer to this study by its ClinicalTrials.gov identifier: NCT01359774
|Hopital de la Pitié-Salpetrière|
|Paris, France, 75013|
|Principal Investigator:||Fanny Mochel, MD, PhD||INSERM UMR S975 Institut du Cerveau et de la Moelle, AP-HP Département de Génétique, Université Pierre et Marie Curie, Paris France|